Publication at First Faculty of Medicine, Second Faculty of Medicine |
2018
Abstract
Young women with reproduction potential form a major population among MS patients. The treatment of their disease should be managed regarding to possible occurrence of pregnancy.
This should be planned, only thus the neurologist can adjust the treatment, so that the foetus would not be endangered by increased risk of abnormal evolution. The paper deals with the risk of individual disease modifying drugs (DMD) used for MS in early pregnancy and also during breastfeeding and brings practical recommendations for individual situations.